Business Wire

TOSHIBA-MATERIALS

Share
Toshiba Materials in Major Investment to Increase Silicon Nitride Ball Production Capacity

Toshiba Materials Co., Ltd. (President: Katsuaki Aoki) today announced a major investment in a new manufacturing facility for silicon nitride balls on the same site as its headquarters in Yokohama, Japan. The project has a budget of over 5-billion yen (approx. US$38 million) and is expected to see production start in November 2023. It will increase capacity by 50% against fiscal year 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220719006169/en/

Continued advances in automobile electrification requires solutions that go beyond higher voltage batteries and shorter charging times. One measure to reduce costs and improve performance is the integration of motors and inverters. Although this increases risk of electrolytic corrosion[1] in motor bearings[2] , the problem can be overcome with hybrid bearings, which replace standard steel balls with ceramic balls with steel inner and outer races. Advantages of high reliability, excellent strength and superior wear resistance are increasingly positioning ceramic balls as the solution of choice.

Toshiba Group has long recognized the potential of fine ceramic products, and won basic patents for silicon nitride compounds as early as 1974. Today, Toshiba Materials, spun off from Toshiba in October 2003, continues to advance R&D and manufacturing of silicon nitride balls, recognized for their reliability and for delivering the highest mechanical performance of any silicon balls. Its experience and record of success in bearing balls that meet demands for high speed rotation and anti-electrolytic corrosion, including machine tools, wind power generators and rolling stock, have won the company about 50% of the world market[3] . With significant increases in demand for bearings for electric vehicles on the horizon, Toshiba Materials has now decided to make this significant investment in increasing capacity.

The new production facility will be built on the company’s headquarters site, where an old building, no longer in use, will be demolished to make way for it. The new facility should be seen as the first phase of expansion, and Toshiba Materials is already considering further expansions to meet future demand growth.

Toshiba Materials will continue stable supply of high quality products, and will contribute to increased use of environmentally friendly electric vehicles.

Features of silicon nitride balls

  • Low density: less than half the weight of a steel ball of the same size
  • High heat resistance
  • Resistant to electrolytic corrosion, as it is an insulator
  • Resistant to corrosion and rust caused by acids and alkalis
  • A non-magnetic material, not easily affected by a strong magnetic field

1 Electrolytic corrosion: damage to a bearing caused by a current flowing through it.
2 Bearing: A part that allows a shaft to rotate smoothly in a machine. Formed with an inner race, balls, and outer race.
3 Toshiba Materials’ investigation, July 2022

About Toshiba Materials

Toshiba Materials Co., Ltd. (http://www.toshiba-tmat.co.jp/en/ ) was spun off from Toshiba Corporation in 2003. With material designing technology as its core capacity, Toshiba Materials supplies materials and components essential for society’s development. Main products include metallic materials, components, fine ceramics parts and chemical materials. In the year ended March 31, 2021, net sales totaled 24.3 billion yen (approx. USD 210 million).

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 01:00:00 CET | Press release

MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind

Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press release

New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041 Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the corne

NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press release

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P

FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press release

Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain an

Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 19:32:00 CET | Press release

First Marketing Authorization granted in France for the treatment of ricin poisoning, one of the most toxic natural substances in the world and a recognized priority biological threat. Ricimed® addresses a previously unmet medical need in the management of severe and potentially fatal ricin intoxications.Supported by the French Ministry of the Armed Forces and Veterans Affairs (the Directorate General of Armaments and the French Military Health Service), the development of Ricimed® illustrates Fabentech’s transition to a new scale and, with recent support from the European HERA Invest program, reinforces its positioning as a reference player in medical countermeasures against biological threats, serving both civilian and military markets. Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release featur

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye